Dovitinib (TKI-258, CHIR-258)|cas 915769-50-5|DC Chemicals

Cas No.:	915769-50-5
Chemical Name:	4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydrate
Synonyms:	4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydrate;4-Amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone 2-hydroxypropanoate hydrate (1:1:1);Dovitinib lactate;Dovitinib;CHIR-258 (TKI-258,Dovitinib);Unii-69vky8p7ea
SMILES:	O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3.CC(O)C(O)=O.[H]O[H]
Formula:	C₂₁H₂₁N₆OF^.C₃H₆O₃^.H₂O
M.Wt:	500.52266
Purity:	99%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor. Dovitinib inhibited proliferation of ZNF198-FGFR1 and BCR-FGFR1 trans Formed Ba/F3 cells with IC50 values of 150 nM and 90 nM, respectively. The phosphorylation of each fusion gene, ERK, and STAT5 was inhibited as well at the same time. Dovitinib also inhibited proliferation of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines and induced apoptosis. Furthermore, dovitinib significantly inhibited the growth of primary cells from 8p11 myeloproliferative syndrome (EMS) patients dose-dependently. For the detailed information about the solubility of Dovitinib (TKI-258, CHIR-258) in water, the solubility of Dovitinib (TKI-258, CHIR-258) in DMSO, the solubility of Dovitinib (TKI-258, CHIR-258) in PBS buffer, the animal experiment（test） of Dovitinib (TKI-258, CHIR-258),the in vivo,in vitro and clinical trial test of Dovitinib (TKI-258, CHIR-258),the cell experiment（test） of Dovitinib (TKI-258, CHIR-258),the IC50, EC50 and Affinity of Dovitinib (TKI-258, CHIR-258), please contact DC Chemicals.

Cat. No.	Product name	Field of application
DC12371	XL-999(Tyrosine kinase-IN-1)	XL999, a Spectrum Selective Kinase Inhibitor(TM) (SSKIs), is a potent inhibitor of key RTKs implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells.
DC1082	ZM306416	ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.
DC1097	XL-184 (Cabozantinib,BMS907351)	XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
DC11268	VEGFR2 kinase inhibitor I(SU-5408)	VEGFR2 kinase inhibitor I(SU-5408)is a potent, cell-permeable inhibitor of mouse VEGFR2 kinase (IC50 = 70 nM).
DC3134	Vandetanib (ZD6474)	Vandetanib (Zactima, ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
DC9586	Telatinib	Telatinib(Bay 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively.
DC12256	TAS-115 mesylate (TAS-115 methanesulfonate)	TAS-115 mesylate is a potent VEGFR and c-Met/HGFR kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
DC3146	Sunitinib malate	Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
DC9781	SU4312(NSC86429)	SU4312(NSC86429) is a selective, cell-permeable inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively).
DC7509	SU1498	SU1498 is a selective inhibitor of the VEGFR2; inhibits Flk-1with an IC50 of value of 700 nM.

Dovitinib (TKI258) Lactate